Vision 2035: The need for Innovation to meet ambitious targets set by the UK’s new critical minerals strategy

​
December 3, 2025

The Government has announced the UK’s new Critical Minerals Strategy, which sets out an ambitious roadmap to secure essential mineral resources. The aim is to meet short term demand and support future development of key growth sectors for the UK’s Modern Industrial Strategy. These sectors include Advanced Manufacturing, Clean Energy Industries, Digital and Technologies, Defence and Life Sciences.  Main commitments include a boost to funding and energy costs relief, as well as streamlining of environmental permitting.

The Critical Minerals Strategy lays out concrete targets to produce 10% of UK’s critical mineral needs domestically by 2035, and a further 20% through recycling.  We can anticipate that a crop of innovative technologies will be developed to meet these targets, given the ever-increasing demand for mineral extraction and processing capabilities. Current activities are not sufficient.

The UK has a high level of innovation capability, and the Critical Minerals Strategy places great emphasis on leveraging this. The government aims to utilise the UK’s strong R&D landscape, including world-class universities and academic centres of research on critical minerals, to propel innovation in technologies essential to Critical Minerals. These include chemistry, metallurgy, geology, midstream processing, recycling and mining engineering. Midstream processing and recycling expertise, in particular, are identified as well-established and growing capabilities of the UK.

What role can intellectual property (IP) play in supporting those working hard to reach the ambitions targets that have been set? The Critical Minerals Strategy does not explicitly comment on IP, despite the undeniable role it will play in the years to come, both home and abroad. Any emergent technology may well become essential to one or more critical minerals sectors, and therefore have worldwide application.  

The patent system requires an owner to disclose their invention in return for the right to prevent others from making use of the invention for a predetermined period of time (typically 20 years). This enables collaborative IP partnerships to be developed, while safeguarding R&D investments and encouraging further innovation. This in contrast to trade secrets that, whilst in theory are perpetual, do not enable innovation based upon the published work of others. Savvy innovators will look to protect their new ideas with IP, likely via patents and/or trade secrets. Given the potential market for successful innovations, holders of IP rights could stand to reap substantial financial benefits and collaboration opportunities. The next decade is a prime opportunity to safeguard innovations via a strong IP strategy.

The Critical Minerals Strategy stresses the importance of international partnership and collaborations, due to the inherent international distribution of natural resources and locations of existing processing capabilities, whilst highlighting that attracting investment to the critical mineral sector can be difficult due to uncertainty introduced by volatile raw material trade prices. This inherent risk can be remedied to some extent by a robust IP portfolio, supported by a deliberate IP strategy. This is because a strong IP portfolio provides intangible assets that are a health and security indicator much sought after by both public and private investors.

A prudent approach to international collaboration and risk management must always include an awareness of IP rights. Protecting those rights gives the owner control over how they are used. Domestically-originating IP may require protection abroad, in strategic jurisdictions, to allow UK businesses to retain their competitive advantage and leverage when expanding or collaborating internationally.  Companies in the sector should also be aware of the present IP landscape to ensure their activities do not infringe upon the rights of others. Licensing or other contractual agreements may be needed if a company does not have freedom to operate in light of IP held by other parties. Such awareness of the IP landscape may also help identify market gaps ready to be explored by R&D, secured by IP and, eventually, capitalised on in the market.

The UK’s critical minerals strategy is a welcome recognition by the government of the role of innovation in the future of the critical minerals industry, to support the green transition, strengthen the UK’s mineral supply chain and drive key growth sectors. A thought-out IP strategy is a vital tool for businesses to demonstrate and safeguard their R&D and better reach their commercial potential.

Further Reading

Department for Business and Trade. (2025). The UK's Modern Industrial Strategy. Policy Paper. Retrieved from https://www.gov.uk/government/publications/industrial-strategy

Department for Business and Trade. (2025). Vision 2035: Critical Minerals Strategy. Policy Paper. Retrieved from https://www.gov.uk/government/publications/uk-critical-minerals-strategy/vision-2035-critical-minerals-strategy

EIP Guide to IP for SMEs

‍

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​